Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSNW), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. This news page for the NRSNW symbol highlights company announcements that describe how NeuroSense is advancing its programs, particularly its lead drug candidate, PrimeC.
NeuroSense’s news flow often centers on clinical development milestones, regulatory interactions and scientific leadership. The company has reported activities such as a proof-of-concept Alzheimer's disease study (RoAD) with top-line safety and tolerability results, preparations for a Phase 3 ALS study, and plans for regulatory steps in Canada for PrimeC in ALS. It has also announced the addition of a world-renowned Alzheimer's disease expert to its Scientific Advisory Board, emphasizing experience in biomarker-driven clinical development and translational neuroscience.
Readers can expect updates related to PrimeC’s progress in ALS and Alzheimer's disease, including study initiations, clinical and biomarker outcome disclosures, and regulatory meetings with agencies such as Health Canada. NeuroSense also uses news releases to outline upcoming investor webinars where it plans to provide business, regulatory and clinical updates, including near-term milestones and program objectives.
For investors and observers tracking NRSNW-related information, this news feed offers a centralized view of NeuroSense’s publicly reported developments around its multi-pathway, biomarker-informed approach to neurodegenerative disease drug development and the ongoing advancement of PrimeC.
NeuroSense (Nasdaq: NRSN) received Nasdaq notification letters on April 2, 2026, for noncompliance with the $1.00 minimum bid rule and the $35M minimum market value of listed securities (MVLS) rule after 30 consecutive business days below each threshold.
These notices do not affect current listing or trading. The company has until September 29, 2026 (180 days) to regain compliance by meeting each metric for 10 consecutive business days and is evaluating actions to restore compliance focused on long-term shareholder value.
NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD 2026 in Copenhagen on March 19, 2026. The presentation reviews Phase 2b PARADIGM findings and biomarker analyses that informed the design of the planned global Phase 3 PARAGON trial.
PARADIGM data were recently published in JAMA Neurology, and NeuroSense says it is actively engaging regulators as PARAGON — a multinational, randomized, double-blind, placebo-controlled study — is advanced to further evaluate PrimeC's safety and efficacy.
NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD™ 2026 on March 19, 2026 in Copenhagen.
The presentation reviews Phase 2b PARADIGM findings, cites publication in JAMA Neurology, and outlines plans for the multinational Phase 3 PARAGON trial while the company maintains regulatory engagement.
NeuroSense (NASDAQ: NRSN) announced JAMA Neurology publication of PARADIGM Phase 2b results for PrimeC in ALS, reporting slower functional decline, reduced complications, and biomarker activity.
Key findings: 7.92-point ALSFRS-R advantage at 18 months (~36% slowing, p=0.007), 64% relative reduction in ALS complications (p=0.02), favorable safety vs placebo, and modulation of iron and microRNA biomarkers.
NeuroSense (NASDAQ: NRSN) will present long-term survival data from the Phase 2b PARADIGM trial of PrimeC at the MDA Clinical & Scientific Conference on March 9, 2026. The analysis showed a 65% reduction in risk of death (HR 0.35; p=0.0037) and a >14-month median survival benefit (36.3 vs. 21.4 months; log-rank p=0.0218).
The randomized, double-blind, placebo-controlled study enrolled 68 participants (2:1 randomization) with a six-month double-blind period followed by an open-label extension; safety was described as favorable.
NeuroSense (NASDAQ: NRSN) reported extended PARADIGM Phase 2b survival data showing a median survival of 36.3 months with continuous PrimeC versus 21.4 months for initial placebo, an improvement of over 14 months (~70% increase).
Adjusted analysis showed a 65% reduction in risk of death (HR 0.35; 95% CI 0.17–0.71; p=0.0037) and a statistically significant log-rank p=0.0218. The randomized 68-patient trial included a 2:1 active:placebo double-blind period and an open-label extension; company engagement with regulators continues.
NeuroSense (NASDAQ: NRSN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,527,768 for a PrimeC combination therapy for Alzheimer's disease, extending patent protection through 2043. The patent covers compositions combining an anti-inflammatory drug and a Dicer activator for neuronal diseases, which the company says strengthens its intellectual property for long-term development and potential commercialization.
NeuroSense also completed a proof-of-concept Alzheimer's study (RoAD) with top-line results showing a favorable safety and tolerability profile. Clinical and biomarker outcomes from the study are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.
The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) said it is resuming regulatory activity in Canada for PrimeC in amyotrophic lateral sclerosis (ALS) after a productive discussion with Health Canada.
Health Canada outlined remaining requirements and confirmed NeuroSense's proposed next steps align with the Agency's expectations. The company is preparing for a pre‑NDS meeting currently contemplated in April 2026. With additional clinical data recently generated and further analyses underway, NeuroSense said it anticipates a potential NDS submission by mid‑2026, pending a successful meeting and completion of final submission components.
NeuroSense will provide more details at an investor webinar on December 8, 2025.
NeuroSense (NASDAQ: NRSN) will host an investor webinar on December 8, 2025 at 8:30 a.m. ET to provide business, regulatory and clinical updates.
Planned topics include the Phase 3 PARAGON study initiation (ALS), submission for Notice of Compliance with conditions (NOC/c) in Canada, the status of a binding term sheet executed in December 2024, and updates on the RoAD Phase 2 program (Alzheimer's disease). Investors can register to attend the webcast.